Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

This stage IV trial examines how a mutation in HSD3B1 (1245C) gene affects treatment of stage I-III breast cancer. This trial may help researchers determine if mutations in HSD3B1 decreases the efficacy of aromatase inhibitor therapy such as letrozole. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Trial Details

NCT ID

NCT05183828

Phase

PHASE4

Sponsor

University of Washington

Status

RECRUITING

Cancer Type

HER2 Negative Breast Cancer

Interventions

Biospecimen Collection
Letrozole
Questionnaire Administration

Locations (sample)

Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

Subject must be female age \>= 18 years.
Postmenopausal as defined by at least one of the following:
Age \>= 60 years;
Age \< 60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; or seru…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →